菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Services for mRNA products

The messenger RNA (mRNA) product class that stems from our microbial production system provides a single-source service for plasmid DNA (pDNA) manufacturing through drug substance (DS) and drug product (DP) production. An expert, well-trained team complements a leading quality system to ensure GMP compatibility.

The service optimizes sequences and process development, encompassing E. coli fermentation, cell lysis, and purification for pDNA; in vitro transcription (IVT) with co-capping and post-capping options and mRNA purification; and encapsulation, ultrafiltration/diafiltration (UF/DF), and fill and finish for LNP. Other key features include seamless technical transfer and effortless scale-up, comprehensive analytical development and quality control (QC) testing, and full CMC and regulatory support.

Contact Us

Key Features

Rapid Timeline

From DNA sequence to IND filing, our mRNA project timelines are exceptionally fast without sacrificing the flexibility needed to achieve your goals. A timeline of only 8 months covers all critical CMC processes.


Diverse Modalities

From pDNA to decorated mRNA-LNP, our mRNA product class supports a variety of biologics products.

Interested in learning more?

Download our flyer

WuXi Biologics is well-equipped for GMP production of DS. To enable scalable pDNA production, our manufacturing facility features a fermenter with capacity that scales up to 150 L. A diversity of vessel volumes and purification equipment support similarly scalable mRNA transcription and purification while increasing the yield.

Separate suites for pDNA linearization, mRNA synthesis, and mRNA purification protect against cross-contamination. In particular, the mRNA purification suite capitalizes on the latest single-use technology. An efficient sequence-to-cell bank process complements an equally streamlined mRNA production process to prepare for DP.

From Sequence to Plasmid DNA

Sequence optimization and synthesis

  • Proprietary plasmid design
  • Sequence synthesis in 2–4 weeks

Strain and clone screening

  • Commercial and in-house E. coli hosts
  • Special detection methods for screening strains with a stable poly(A) and supercoiled monomers ratio

Bacterial cell banking

  • PD and GMP cell banking
  • Cell bank release testing and storage

Plasmid production

  • Quick plug-in platform fermentation and purification process
  • Fermentation toolbox for titer and quality improvements

WuXi Biologics provides a matrix of vector backbones with different designs of promoters, UTRs, polyA, restriction sites, and more.

From Plasmid DNA to mRNA Drug Substance

mRNA Production Process

pDNA linearization

  • Selection of restriction enzyme
  • Optimization of reagent concentration and reaction conditions to ensure complete linearization
  • Reaction volume scale-up from μL to L

Purification of linearized pDNA

  • Tangential flow filtration (TFF) and chromatography (optional)

In vitro transcription

  • With or without cap analogs
  • Optimization of reagent concentration and reaction conditions to achieve high yield, minimal by-products, and low residue
  • Reaction volume scale-up from μL to L

mRNA purification

  • TFF
  • Affinity chromatography
  • Optional polish (HIC, MMC or fiber; B&E model or FT model)

High-Performance mRNA Platform

Key Strengths

  • High yield and high recovery
  • Consistent and scalable process that supports 0.5–50 L mRNA GMP production
  • High product quality with high purity, minimal impurities, and low residue

Both DP stages, development and manufacturing, benefit from state-of-the art mRNA-LNP drug development systems and aseptic filling systems. Powered by robotics, the aseptic filling systems minimize hands-on time, and the risks associated with manual systems.

DP development includes formulation development, process development, and technology transfer and features the following technology:

  • Various RNA molecule encapsulations (e.g., mRNA, circRNA, saRNA, co-encapsulation, etc.)
  • Various DP forms: liquid, frozen liquid, and lyophilized
  • Full-scope DP development, including formulation and process
  • Microfluidic and T-junction mixing technologies
  • Bridging study from microfluidic to T-junction to support GMP manufacturing
  • Encapsulation scale of 25 µL to 10 L (material generation, feasibility, and pilot)
  • Stability, stress study, CCIT, and clinical in-use study
  • Extensive mRNA-LNP DP characterization techniques: particle size, PDI, encapsulation efficiency, mRNA concentration, and more

DP manufacturing features the following technology:

LNP encapsulation

  • Impingement jets mixing (IJM) technology for LNP encapsulation
  • Single-use systems
  • General capacity of 1.5–20 L per batch

DP fill and finish

  • Robotic filling machine (isolator) for liquid DP manufacturing
  • Syntegon isolator filling machine equipped with GEA 7m2 freeze dryer for lyo vial products

Our dedicated team of well-trained and experienced analytical and QC professionals allows us to offer:

  • Integrated labs that support diverse mRNA modalities
  • Methods development, transfer, and qualification and validation
  • Product biochemical, biophysical, and biological characterization and comparability analysis
  • Comprehensive analytical capabilities for full CMC packages that enable IND and BLA filings
  • Tox/clinical lot DS/DP release and stability testing
  • Reference standard generation, qualification, characterization, storage, and lifetime management
  • Analytical investigation and troubleshooting for issues related to GMP manufacturing

WuXi Biologics has an ingrained commitment to quality. Our global quality system, QC, and operational systems are well-established and meet or exceed standards set by the FDA, EMA, NMPA, and other major regulatory agencies worldwide

We have harmonized our quality assurance (QA) and quality management system across all global sites. This approach maximizes efficiency and quality for confidence in the clinical and commercial production of DS and DP, both biologic and vaccine.

Connect with our Experts

Let’s discuss your project needs.
Contact Us